Free tool
Rare disease stocks
We cover 34 companies grouped under the Rare disease theme. The median market value in the group is $3.18B. Across the group, the median move over the past trading day is −0.05%. 84% of the 32 with a 200-day average trade above it. Price change over the past year runs from +11.2% to +261.5% across the middle 80 percent of the group, with a median of +76.8%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
34 of 268 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return | Next report |
|---|---|---|---|---|---|
| PTGX | Protagonist Therapeutics, Inc. | $9.80B | Mid cap | +146.62% | Nov 5, 2026 |
| IMVT | Immunovant, Inc. | $9.07B | Mid cap | +189.13% | Nov 9, 2026 |
| CRNX | Crinetics Pharmaceuticals, Inc. | $9.00B | Mid cap | +179.08% | Nov 5, 2026 |
| RYTM | Rhythm Pharmaceuticals, Inc. | $7.78B | Mid cap | +9.35% | Nov 3, 2026 |
| SRRK | Scholar Rock Holding Corporation | $7.31B | Mid cap | +74.18% | Nov 12, 2026 |
| ORKA | Oruka Therapeutics, Inc. | $6.58B | Mid cap | +555.07% | Nov 11, 2026 |
| LQDA | Liquidia Corporation | $6.31B | Mid cap | +154.86% | Nov 3, 2026 |
| TVTX | Travere Therapeutics, Inc. | $6.24B | Mid cap | +284.86% | Oct 29, 2026 |
| DNTH | Dianthus Therapeutics, Inc. | $6.13B | Mid cap | +356.93% | Nov 5, 2026 |
| PTCT | PTC Therapeutics, Inc. Common Stock | $6.07B | Mid cap | +46.02% | Nov 5, 2026 |
| KNSA | Kiniksa Pharmaceuticals International, plc | $6.05B | Mid cap | +133.47% | Oct 27, 2026 |
| MIRM | Mirum Pharmaceuticals, Inc. | $5.98B | Mid cap | +31.96% | Nov 4, 2026 |
| DYN | Dyne Therapeutics, Inc. | $4.92B | Mid cap | +93.26% | Nov 5, 2026 |
| EWTX | Edgewise Therapeutics, Inc. | $4.80B | Mid cap | +207.13% | Nov 5, 2026 |
| MANE | Veradermics, Incorporated | $4.29B | Mid cap | +172.32% | Nov 12, 2026 |
| AMLX | Amylyx Pharmaceuticals, Inc. | $4.13B | Mid cap | +292.38% | Nov 5, 2026 |
| CLDX | Celldex Therapeutics, Inc. | $3.19B | Mid cap | +79.51% | Nov 9, 2026 |
| IRON | Disc Medicine, Inc. | $3.17B | Mid cap | +37.90% | Nov 5, 2026 |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.12B | Mid cap | +60.64% | Oct 27, 2026 |
| VRDN | Viridian Therapeutics, Inc. | $2.75B | Mid cap | +30.71% | Nov 5, 2026 |
| VERA | Vera Therapeutics, Inc. | $2.65B | Mid cap | +67.21% | Nov 5, 2026 |
| RARE | Ultragenyx Pharmaceutical Inc. | $2.61B | Mid cap | −12.10% | Nov 3, 2026 |
| PHVS | Pharvaris N.V. | $2.60B | Mid cap | +55.59% | Nov 12, 2026 |
| TRVI | Trevi Therapeutics, Inc. | $2.55B | Mid cap | +124.00% | Nov 12, 2026 |
| NKTR | Nektar Therapeutics | $2.52B | Mid cap | +151.95% | Nov 12, 2026 |
| BCRX | BioCryst Pharmaceuticals, Inc. | $2.51B | Mid cap | +15.38% | Nov 2, 2026 |
| COAG | Hemab Therapeutics Holdings, Inc. | $2.30B | Mid cap | +44.68% | Nov 16, 2026 |
| MLYS | Mineralys Therapeutics, Inc. | $2.28B | Mid cap | +70.22% | Nov 10, 2026 |
| PVLA | Palvella Therapeutics, Inc. | $2.22B | Mid cap | +173.39% | Nov 11, 2026 |
| AUPH | Aurinia Pharmaceuticals Inc. | $2.20B | Mid cap | +36.58% | Nov 9, 2026 |
| ADMA | ADMA Biologics, Inc. | $2.16B | Mid cap | −44.17% | Nov 4, 2026 |
| ZBIO | Zenas BioPharma, Inc. | $2.15B | Mid cap | +97.73% | Nov 12, 2026 |
| STOK | Stoke Therapeutics, Inc. | $2.14B | Mid cap | +71.45% | Nov 3, 2026 |
| AGIO | Agios Pharmaceuticals, Inc. Common Stock | $2.03B | Mid cap | −13.45% | Oct 29, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.